Home › Funds › Vanguard › Vanguard U.S. Multifactor Fund
Fund family: Vanguard · Filed by VANGUARD WELLINGTON FUND (CIK 105563) · SEC series S000061303
Ticker: VFMFX (C000198467)
“With management” counts the items where the fund’s own filing gives management’s recommendation (FOR or AGAINST): 5,919 with, 179 against, 0 abstentions (not counted as with management). Shareholder proposals: 8 FOR, 165 AGAINST, 0 abstained, by the filing’s own vote-source field.
The same two figures as Vanguard’s manager page (1,379,791 ballot items across 136 funds and accounts), counted the same way for this fund.
| 2025-2026 | This fund | Items | Vanguard | Items |
|---|---|---|---|---|
| Voted FOR the board's own proposals (directors, pay, auditor, capital, transactions, fund matters) | 98.8% | 5,807 | 94.5% | 1,082,514 |
| Backed environmental and social shareholder proposals at US companies | 0.0% | 82 | 0.9% | 6,718 |
Each ballot item this fund voted is set against the votes of the other Vanguard funds and accounts on the same item (same meeting, same proposal): “most funds” is a strict majority of at least three of them, FOR against AGAINST, WITHHOLD or ABSTAIN, with split votes and items not voted left out. Funds in one family can follow separate voting policies, for example ESG funds, sub-advised funds and funds using pass-through voting.
Voted the same way as most Vanguard funds on all 6,034 items where a comparison was possible.
The same votes as “with management” above, by the sector of the company voted on. 96.2% of this fund’s 6,098 such votes could be given a sector; the other 234 (3.8%) are at companies without one and are not in the table.
| Sector | Votes | Against management | Share |
|---|---|---|---|
| Finance | 1,512 | 30 | 2.0% |
| Consumer Discretionary | 1,468 | 45 | 3.1% |
| Health Care | 764 | 23 | 3.0% |
| Technology | 693 | 41 | 5.9% |
| Industrials | 618 | 20 | 3.2% |
| Energy | 318 | 3 | 0.9% |
| Consumer Staples | 205 | 10 | 4.9% |
| Telecommunications | 115 | 6 | 5.2% |
| Real Estate | 70 | 0 | 0.0% |
| Miscellaneous | 40 | 0 | 0.0% |
| Basic Materials | 38 | 0 | 0.0% |
| Utilities | 23 | 0 | 0.0% |
| Proposal type | Items | Against management |
|---|---|---|
| Director Elections | 4,423 | 4 |
| Audit-related | 565 | 0 |
| Say-on-Pay | 563 | 2 |
| Compensation | 215 | 5 |
| Corporate Governance | 180 | 79 |
| Capital Structure | 51 | 0 |
| Environment or Climate | 36 | 36 |
| Extraordinary Transactions | 33 | 0 |
| Other Social Issues | 31 | 30 |
| Shareholder Rights and Defenses | 17 | 7 |
Position = shares voted × a recent share price, for US-listed shares of companies with a page on this site; an estimate for ranking only.
| Company | Meeting | Est. position | Items | Against mgmt |
|---|---|---|---|---|
| Micron Technology, Inc. | January 15, 2026 | $11M | 12 | 1 |
| The Bank of New York Mellon Corporation | April 14, 2026 | $6M | 13 | 0 |
| AbbVie Inc. | May 8, 2026 | $5M | 8 | 1 |
| Gilead Sciences, Inc. | April 30, 2026 | $5M | 15 | 3 |
| Regeneron Pharmaceuticals, Inc. | June 12, 2026 | $5M | 7 | 0 |
| Altria Group, Inc. | May 14, 2026 | $5M | 12 | 0 |
| Newmont Corporation | May 12, 2026 | $5M | 14 | 0 |
| Merck & Co., Inc. | May 26, 2026 | $4M | 18 | 3 |
| Meeting | Company | Proposal | Fund | Mgmt |
|---|---|---|---|---|
| January 15, 2026 | Micron Technology, Inc. | SHAREHOLDER PROPOSAL REQUESTING AMENDMENT TO SHAREHOLDER SPECIAL MEETING RIGHT. Shareholder proposal | Against | For |
| May 8, 2026 | AbbVie Inc. | Stockholder Proposal - to Adopt a Policy to Require an Independent Chair Shareholder proposal | Against | For |
| April 30, 2026 | Gilead Sciences, Inc. | To vote on a stockholder proposal requesting an independent Board Chair policy, if properly presented at the Annual Meeting. Shareholder proposal | Against | For |
| April 30, 2026 | Gilead Sciences, Inc. | To vote on a stockholder proposal requesting a report on the impact of extended patent exclusivities on patient access, if properly presented at the Annual Meeting. Shareholder proposal | Against | For |
| May 26, 2026 | Merck & Co., Inc. | Shareholder proposal regarding a report on DEI risks in federal contracting. Shareholder proposal | Against | For |
| May 26, 2026 | Merck & Co., Inc. | Shareholder proposal regarding a report on healthcare coverage gaps. Shareholder proposal | Against | For |
| May 19, 2026 | Amgen Inc. | Stockholder proposal to require an independent board chairman. Shareholder proposal | Against | For |
| April 23, 2026 | HCA Healthcare, Inc. | Stockholder proposal, if properly presented at the meeting, regarding a report on healthcare consequences. Shareholder proposal | Against | For |
| April 23, 2026 | HCA Healthcare, Inc. | Stockholder proposal, if properly presented at the meeting, regarding stockholders' right to act by written consent. Shareholder proposal | Against | For |
| May 5, 2026 | Bristol-Myers Squibb Company | Shareholder Proposal on the Adoption of a Board Policy that the Chairperson of the Board be an Independent Director Shareholder proposal | Against | For |
| May 14, 2026 | CVS Health Corporation | Stockholder Proposal for Reducing the Threshold for Our Stockholder Right to Act By Written Consent. Shareholder proposal | Against | For |
| December 16, 2025 | Cisco Systems, Inc. | Stockholder Proposal - Approval to request the Board to conduct an evaluation and issue a report assessing how Cisco's Inclusion programs provide positive financial value to shareholders. Shareholder proposal | Against | For |
Meetings with a proxy contest or competing nominees (3 in 2025-2026), and how the fund voted the items on its ballot.
6,130 ballot items at 580 meetings in 2025-2026. Download all votes (CSV)
Recent votes against management’s recommendation at large companies.
In the 2025-2026 proxy season, Vanguard U.S. Multifactor Fund (VFMFX) voted at 580 shareholder meetings of 571 companies, on 6,130 ballot items in all. Where management made a recommendation, the fund followed it on 97.1% of the items and voted against it 179 times. Its most frequent area of disagreement was corporate governance (79 of its votes against management). It voted FOR 4.6% of the 173 shareholder proposals on which it cast a FOR or AGAINST vote. It voted FOR the board's own proposals more often than Vanguard's funds as a whole (98.8% against 94.5%). It voted the same way as most Vanguard funds on every item where a comparison was possible. 3 of its meetings were contested.
Every figure is derived from the fund’s own Form N-PX filings with the SEC, read item by item: one ballot item is the fund’s vote on one proposal at one meeting, and an item filed twice in the season is counted once. Percentages count items, never shares. A season is published only with at least 250 ballot items at 15 meetings. Built November 18, 2026; the family figures are those of Vanguard’s manager page. The interactive database shows the same votes company by company, with every other fund that voted.